Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Global Seborrhea Market 2016 Share, Trend, Segmentation and Forecast to 2022

Monday, October 10, 2016 5:07
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary

Global Markets Direct’s, ‘Seborrhea – Pipeline Review, H2 2016’, provides an overview of the Seborrhea pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Seborrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Seborrhea and features dormant and discontinued projects.

Complete report details @ https://www.wiseguyreports.com/reports/649780-seborrhea-pipeline-review-h2-2016

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Seborrhea 
- The report reviews pipeline therapeutics for Seborrhea by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Seborrhea therapeutics and enlists all their major and minor projects 
- The report assesses Seborrhea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Seborrhea

Request a sample report @ https://www.wiseguyreports.com/sample-request/649780-seborrhea-pipeline-review-h2-2016

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Seborrhea 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Seborrhea pipeline depth and focus of Indication therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/649780-seborrhea-pipeline-review-h2-2016

Key points in table of content

Table of Contents 
Table of Contents 2 
List of Tables 4 
List of Figures 4 
Introduction 5 
Global Markets Direct Report Coverage 5 
Seborrhea Overview 6 
Therapeutics Development 7 
Pipeline Products for Seborrhea – Overview 7 
Seborrhea – Therapeutics under Development by Companies 8 
Seborrhea – Pipeline Products Glance 9 
Late Stage Products 9 
Clinical Stage Products 10 
Early Stage Products 11 
Seborrhea – Products under Development by Companies 12 
Seborrhea – Companies Involved in Therapeutics Development 13 
Aclaris Therapeutics Inc 13 
Amorepacific Corporation 14 
Biomar Microbial Technologies 15 
EpiPharm AG 16 
Phosphagenics Limited 17 
Seborrhea – Therapeutics Assessment 18 
Assessment by Monotherapy Products 18 
Assessment by Target 19 
Assessment by Mechanism of Action 21 
Assessment by Route of Administration 23 
Assessment by Molecule Type 25 
Drug Profiles 26 
artemether – Drug Profile 26 
Product Description 26 
Mechanism Of Action 26 
R&D Progress 26 
hydrogen peroxide – Drug Profile 27 
Product Description 27 
Mechanism Of Action 27 
R&D Progress 27 
IB-07A081 – Drug Profile 29 
Product Description 29 
Mechanism Of Action 29 
R&D Progress 29 
IB-07A085 – Drug Profile 30 
Product Description 30 
Mechanism Of Action 30 
R&D Progress 30 
ketoconazole – Drug Profile 31 
Product Description 31 
Mechanism Of Action 31 
R&D Progress 31 
PAC-14028 – Drug Profile 32 
Product Description 32 
Mechanism Of Action 32 
R&D Progress 32 
Seborrhea – Dormant Projects 34 
Seborrhea – Discontinued Products 35 
Seborrhea – Product Development Milestones 36 
Featured News & Press Releases 36 
Jul 25, 2016: Aclaris Therapeutics Completes Enrollment of Phase 3 Pivotal Trials of A-101 for the Treatment of Seborrheic Keratosis; Provides Update on Clinical Programs 36 
Jan 19, 2016: Aclaris Therapeutics Initiates Phase 3 Clinical Trials of A-101 for the Treatment of Seborrheic Keratosis 36 
Mar 17, 2015: Aclaris Therapeutics’ Lead Drug Candidate A-101 Achieves Statistically Significant Results in Third Phase 2 Clinical Trial for Seborrheic Keratosis, a Common Type of Benign Skin Tumor 36 
Jan 27, 2015: Aclaris Therapeutics Announces Positive Results from Phase 2b Clinical Trial of A-101 for the Removal of Seborrheic Keratosis, a Common Type of Benign Skin Tumor 37 
Jun 30, 2014: Aclaris Therapeutics Announces Positive Results from Phase 2 Clinical Trial of A-101 for the Removal of Seborrheic Keratosis, a Common Type of Skin Tumor 38 
Appendix 39 
Methodology 39 
Coverage 39 
Secondary Research 39 
Primary Research 39 
Expert Panel Validation 39 
Contact Us 39 
Disclaimer 40

List of Tables 
Number of Products under Development for Seborrhea, H2 2016 7 
Number of Products under Development by Companies, H2 2016 8 
Comparative Analysis by Late Stage Development, H2 2016 9 
Comparative Analysis by Clinical Stage Development, H2 2016 10 
Comparative Analysis by Early Stage Development, H2 2016 11 
Products under Development by Companies, H2 2016 12 
Seborrhea – Pipeline by Aclaris Therapeutics Inc, H2 2016 13 
Seborrhea – Pipeline by Amorepacific Corporation, H2 2016 14 
Seborrhea – Pipeline by Biomar Microbial Technologies, H2 2016 15 
Seborrhea – Pipeline by EpiPharm AG, H2 2016 16 
Seborrhea – Pipeline by Phosphagenics Limited, H2 2016 17 
Assessment by Monotherapy Products, H2 2016 18 
Number of Products by Stage and Target, H2 2016 20 
Number of Products by Stage and Mechanism of Action, H2 2016 22 
Number of Products by Stage and Route of Administration, H2 2016 24 
Number of Products by Stage and Molecule Type, H2 2016 25 
Seborrhea – Dormant Projects, H2 2016 34 
Seborrhea – Discontinued Products, H2 2016 35

Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=649780

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.